2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report 2024 13 March 2025 at 4.00 p.m.: Annual General Meeting ALK ...

Ensacove is approved for ALK-positive NSCLC patients who haven't received prior ALK-inhibitors, offering a new first-line treatment option. The eXALT3 trial showed Ensacove significantly improved ...

Data supplied by Morningstar and accurate on Sep 18, 2024. It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of ...